Combination Chemotherapy in Patients With Malignant Pleural Effusions From Non-small Cell Lung Cancer
Authors:
- Akihisa FujitaAFAkihisa Fujita
- Hirotsugu TakabatakeHTHirotsugu Takabatake
- Shigeru TagakiSTShigeru Tagaki
- Kyuhichiro SekineKSKyuhichiro Sekine
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancerCancer Chemotherapy and Pharmacology, 2000
- Phase I Study of Cisplatin, Ifosfamide and Irinotecan with rhG-CSF Support in Advanced Non-Small Cell Lung CancerOncology, 1999
- Prospective Randomized Trial of Talc Slurry vs Bleomycin in Pleurodesis for Symptomatic Malignant Pleural Effusions*Chest, 1997
- Management of Malignant Pleural EffusionsChest, 1993
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992
- Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A Randomized TrialCancer, 1992
- A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancerCancer, 1991
- Isolated Pleural Effusion in Small Cell Lung Carcinoma: Favorable PrognosisChest, 1982
- Management of Pleural Effusions in Breast CancerChest, 1979
- The treatment of malignant pleural effusionsCancer, 1974